Protein microarrays identify antibodies to protein kinase C that are associated with a greater risk of allograft loss in pediatric renal transplant recipients

Kidney International

Volumn 76, Issue 12, 2009, Pages 1277-1283

  Sutherland, Scott M ^a   Li, Li ^a   Sigdel, Tara K ^a   Wadia, Persis P ^a   Miklos, David B ^a   Butte, Atul J ^b   Sarwal, Minnie M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute rejection; Pediatric kidney transplantation; Renal transplantation

Indexed keywords

ANTIGEN; COMPLEMENT COMPONENT C4D; HLA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN KINASE C ZETA; TACROLIMUS;

ADOLESCENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CELL INFILTRATION; CHILD; CLINICAL ARTICLE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY TRANSPLANTATION; LYMPHOCYTE; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN MICROARRAY; RISK FACTOR; SCHOOL CHILD;

ADOLESCENT; CHILD; COMPLEMENT C4B; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; ISOANTIBODIES; ISOANTIGENS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; PEPTIDE FRAGMENTS; PROTEIN ARRAY ANALYSIS; PROTEIN KINASE C; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 71149110127     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.384     Document Type: Article

References (28)

1. Wissing KM, Fomegné G, Broeders N et al. HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies. Transplantation 2008; 85: 411-416.
2. Hariharan S, Johnson CP, Bresnahan BA et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612.
3. Mao Q, Terasaki PI, Cai J et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864-871.
4. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365: 1570-1576.
5. Collins AB, Chicano SL, Cornell LD et al. Putative antibody-mediated rejection with C4d deposition in HLA-identical, ABO-compatible renal allografts. Transplant Proc 2006; 38: 3427-3429.
6. Carter V, Shenton BK, Jaques B et al. Vimentin antibodies: a non-HLA antibody as a potential risk factor in renal transplantation. Transplant Proc 2005; 37: 654-657.
7. Dragun D, Müller DN, Bräsen JH et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-569.
8. Zou Y, Stastny P, Süsal C et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293-1300.
9. Sun Q, Liu Z, Yin G et al. Detectable circulating antiendothelial cell antibodies in renal allograft recipients with C4d-positive acute rejection: a report of three cases. Transplantation 2005; 79: 1759-1762.
10. Sun Q, Liu Z, Chen J et al. Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection. Clin J Am Soc Nephrol 2008; 3: 1479-1486.
11. Dragun D. Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation. Transplantation 2008; 86: 1019-1025.
12. Tinckam KJ, Chandraker A. Mechanisms and role of HLA and non-HLA alloantibodies. Clin J Am Soc Nephrol 2006; 1: 404-414.
13. Hudson ME, Pozdnyakova I, Haines K et al. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci USA 2007; 104: 17494-17499.
14. Robinson WH, DiGennaro C, Hueber W et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat med 2002; 8: 295-301.
15. Li L, Wadia P, Chen R et al. Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and ''antibodyome'' measures. Proc Natl Acad Sci 2009; 106: 4148-4153.
16. Leitges M, Sanz L, Martin P et al. Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. Mol Cell 2001; 8: 771-780.
17. Leroy I, de Thonel Al, Laurent G et al. Protein kinase C zeta associates with death inducing signaling complex and regulates Fas ligand-induced apoptosis. Cell Signal 2005; 17: 1149-1157.
18. Leseux L, Laurent G, Laurent C et al. PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood 2008; 111: 285-291.
19. Padanilam BJ. Induction and subcellular localization of protein kinase C isozymes following renal ischemia. Kidney Int 2001; 59: 1789-1797.
20. San-Antonio B, Iñiguez MA, Fresno M. Protein kinase Czeta phosphorylates nuclear factor of activated T cells and regulates its transactivating activity. J Biol Chem 2002; 277: 27073-27080.
21. Xin M, Gao F, May WS et al. Protein kinase Czeta abrogates the proapoptotic function of Bax through phosphorylation. J Biol Chem 2007; 282: 21268-21277.
22. Zhao Y, Fishelevich R, Petrali JP et al. Activation of keratinocyte protein kinase C zeta in psoriasis plaques. J Invest Dermatol 2008; 128: 2190-2197.
23. Huang X, Chen L-Y, Doerner A et al. An atypical protein kinase C (PKC zeta) plays a critical role in lipopolysaccharide-activated NF-kappa B in human peripheral blood monocytes and macrophages. J Immunol 2009; 182: 5810-5815.
24. Chen C, Johnston T, Jeon H et al. Cyclosporin A up-regulates and activates protein kinase C-zeta in EBV-infected and EBV-transformed human B-cells. J Surg Res 2009; 153: 156-161.
25. SOURCE Search for PRKCZ. http://smd.stanford.edu/cgi-bin/source/ sourceResult. Accessed on June 2008.
26. Barros SA, Srimaroeng C, Perry JL et al. Activation of protein kinase c{zeta} increases OAT1 (SLC22A6)-and OAT3 (SLC22A8)-mediated transport. J Biol Chem 2009; 284: 2672-2679.
27. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723. (Pubitemid 29082898)
28. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753-760. (Pubitemid 351347767)